PVLA Earnings & Financial Statements
Palvella Therapeutics, Inc.
$127.34
+$4.76(+3.88%)
38
Overall
40
Value
36
Tech
39
Quality
Market Cap
$1.77B
Volume
240.97K
52W Range
$66.58 - $161.38
Target Price
$229.19
PVLA earnings and financial statements: Palvella Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
PVLA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | $42.81M | $25.90M | $31.42M |
| Operating income | -$38.60M | -$14.10M | -$11.87M | -$43.91M | -$51.83M |
| EBITDA | -$44.30M | -$17.65M | $18.69M | -$32.52M | -$46.96M |
| Net income | -$41.72M | -$17.43M | $18.69M | -$33.28M | -$45.74M |
| EPS (diluted) | $-3.71 | $-7.83 | $-21.60 | $-0.45 | $-0.71 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $59.56M | $88.23M | $7.55M | $95.49M | $153.56M |
| Total liabilities | $31.58M | $25.63M | $11.43M | $67.56M | $102.81M |
| Shareholders’ equity | $27.98M | $62.61M | -$74.48M | $27.93M | $50.76M |
| Cash and equivalents | $57.98M | $83.60M | $7.35M | $38.63M | $117.76M |
| Long-term debt | $431.0K | - | - | $12.24M | $13.84M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$25.01M | -$10.84M | -$13.70M | -$14.84M | -$7.66M |
| Capital expenditure | - | - | -$171.0K | -$1.04M | -$949.0K |
| Free cash flow | -$25.01M | -$10.84M | -$13.70M | -$14.84M | -$8.61M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PVLA | $127.34 | +3.9% | 240.97K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Palvella Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW